AU2001270778A1 - Production, stabilisation and use of reduced forms of pharmaceutical compounds - Google Patents

Production, stabilisation and use of reduced forms of pharmaceutical compounds

Info

Publication number
AU2001270778A1
AU2001270778A1 AU2001270778A AU7077801A AU2001270778A1 AU 2001270778 A1 AU2001270778 A1 AU 2001270778A1 AU 2001270778 A AU2001270778 A AU 2001270778A AU 7077801 A AU7077801 A AU 7077801A AU 2001270778 A1 AU2001270778 A1 AU 2001270778A1
Authority
AU
Australia
Prior art keywords
stabilisation
production
pharmaceutical compounds
reduced forms
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270778A
Inventor
Anthony Atkinson
Andrew Marc Salomon
Ernest Wulfert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Fleming Ltd
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of AU2001270778A1 publication Critical patent/AU2001270778A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001270778A 2000-07-11 2001-07-10 Production, stabilisation and use of reduced forms of pharmaceutical compounds Abandoned AU2001270778A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0017060.5A GB0017060D0 (en) 2000-07-11 2000-07-11 Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0017060 2000-07-11
PCT/GB2001/003102 WO2002004025A1 (en) 2000-07-11 2001-07-10 Production, stabilisation and use of reduced forms of pharmaceutical compounds

Publications (1)

Publication Number Publication Date
AU2001270778A1 true AU2001270778A1 (en) 2002-01-21

Family

ID=9895475

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001270778A Abandoned AU2001270778A1 (en) 2000-07-11 2001-07-10 Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001269314A Abandoned AU2001269314A1 (en) 2000-07-11 2001-07-10 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001269314A Abandoned AU2001269314A1 (en) 2000-07-11 2001-07-10 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds

Country Status (6)

Country Link
US (2) US20030181389A1 (en)
EP (2) EP1301181A2 (en)
JP (2) JP2004502743A (en)
AU (2) AU2001270778A1 (en)
GB (1) GB0017060D0 (en)
WO (2) WO2002003972A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US7579325B2 (en) 2001-03-21 2009-08-25 Eisai R & D Management Co., Ltd. Drugs containing reduced of vitamin B2
JP3742602B2 (en) * 2001-05-09 2006-02-08 株式会社カネカ Stable solution of reduced coenzyme Q
JP4684553B2 (en) * 2001-09-27 2011-05-18 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア Regulation of physiological processes and drugs useful for this
JP3822479B2 (en) * 2001-10-10 2006-09-20 株式会社カネカ Stabilized composition of reduced coenzyme Q aqueous solution
US20060211748A1 (en) * 2002-07-11 2006-09-21 Bain Allen I Sulphydryl compounds in combination with sulpha compounds
EP1768676A1 (en) * 2004-07-22 2007-04-04 ThioMatrix Forschungs- und Beratungs GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
JPWO2006104153A1 (en) * 2005-03-29 2008-09-11 株式会社カネカ Composition for enhancing antioxidant activity in blood
CN104529939B (en) 2006-03-29 2019-05-07 维斯塔实验室有限公司 3,7- diaminostilbene 0H- phenothiazine compounds salt and application thereof
EP2004155B1 (en) 2006-03-29 2018-02-21 WisTa Laboratories Ltd. Inhibitors of protein aggregation
WO2008073902A2 (en) * 2006-12-12 2008-06-19 Cytyc Corporation Method for improving the shelf-life of hematoxylin staining solutions
CA2690746C (en) * 2007-06-19 2018-01-02 Wista Laboratories Ltd Phenothizine compounds for treating mild cognitive impairment
PT2954932T (en) * 2007-10-03 2018-12-12 Wista Lab Ltd Therapeutic use of diaminophenothiazines
CN101655449A (en) * 2008-08-20 2010-02-24 鸿富锦精密工业（深圳）有限公司 Device for measuring catalytic performance of photocatalyst
US8796448B1 (en) * 2010-12-09 2014-08-05 Prosetta Antiviral Inc. Compounds, compositions, and methods for treating Alzheimer's disease
CN103209699A (en) * 2010-09-23 2013-07-17 北德克萨斯大学保健科学中心 Compounds that enable alternative mitochondrial electron transfer
SI2673266T1 (en) 2011-02-11 2016-11-30 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
JP6370674B2 (en) 2014-10-22 2018-08-08 国立研究開発法人国立長寿医療研究センター Tauopathy drug and screening method thereof
US11413240B2 (en) * 2016-12-29 2022-08-16 Board Of Regents, The University Of Texas System Methylene blue solution for the treatment of oral lesions
JP2018070581A (en) * 2017-04-19 2018-05-10 誠一 荒木 Reduced-vitamin b2 formulation
KR20230012515A (en) * 2020-05-05 2023-01-26 위스타 레보레이토리스 리미티드 beneficial treatment methods
GB202204185D0 (en) * 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414212A (en) * 1981-12-10 1983-11-08 Graham J. Naylor Method of treatment of pre-menstrual syndrome
US4711894A (en) * 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
US5075116A (en) * 1989-04-20 1991-12-24 Lahaye Laboratories, Inc. Composition and method for treatment of macular degeneration
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9323399D0 (en) * 1993-11-12 1994-01-05 Univ Newcastle Ventures Ltd Pharmaceutical formulations
AU708682B2 (en) * 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache

Also Published As

Publication number Publication date
EP1299125A1 (en) 2003-04-09
WO2002004025A1 (en) 2002-01-17
WO2002003972A3 (en) 2002-10-24
WO2002003972A2 (en) 2002-01-17
JP2004502743A (en) 2004-01-29
US20030181389A1 (en) 2003-09-25
EP1301181A2 (en) 2003-04-16
GB0017060D0 (en) 2000-08-30
AU2001269314A1 (en) 2002-01-21
US20040033936A1 (en) 2004-02-19
JP2004502728A (en) 2004-01-29

Similar Documents

Publication Publication Date Title
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
AU2002363005A1 (en) Derivatives of uk-2a
AU2002257497A1 (en) Derivatives of exendin
AU2682401A (en) Flavonoid drug and dosage form, its production and use
AU2002365516A1 (en) Benzamide derivatives, processes for their preparation, and their pharmaceutical use
AU2002223647A1 (en) Aryl-substituted indirubin derivatives, the production thereof and use of the same
AU2002359126A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2002351764A1 (en) Flavonoid compounds and their pharmaceutical uses
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
AU2002359123A1 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2001232948A1 (en) Controlled release of drugs
AU2001297611A1 (en) Pharmaceutical uses and synthesis of diketopiperazines
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001232244A1 (en) Drug comprising combination
AU2001265935A1 (en) Production of biohydrolysates
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
AU2002229870A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
WO2001074787A3 (en) Crystalline pharmaceutical
AU2002308105A1 (en) Benzoaxathiepin derivatives and their use as medicines